[1]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158-159.[doi:10.3969/j.issn.1006-1959.2020.07.052]
　DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Medical Information,2020,33(07):158-159.[doi:10.3969/j.issn.1006-1959.2020.07.052]
点击复制

达格列净治疗2型糖尿病的疗效及其对体质指数的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
158-159
栏目:
药物与临床
出版日期:
2020-04-01

文章信息/Info

Title:
The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index
文章编号:
1006-1959（2020）07-0158-02
作者:
董 健
（武清区人民医院内分泌科，天津 301700）
Author(s):
DONG Jian
(Department of Endocrinology,Wuqing District People’s Hospital,Tianjin 301700,China)
关键词:
达格列净; 2型糖尿病; 疗效; 安全性; 体质指数
Keywords:
Dapagliflozin; Type 2 diabetes; Efficacy; Safety; Body mass index
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2020.07.052
文献标志码:
A
摘要:
目的 观察达格列净治疗2型糖尿病的疗效、安全性及其对体质指数的影响。方法 选取2017年4月~12月在我院诊治的153例2型糖尿病患者为研究对象，采用随机数字表法分为对照组（n=75）和观察组（n=78）。对照组采用二甲双胍治疗，观察组采用达格列净治疗，比较两组治疗疗效、治疗后空腹血糖（FBG）水平、糖化血红蛋白（HbA1c）、体重指数（BMI）、血压、肾功能指标[尿酸（UA）、尿微量白蛋白（mAlb）]、病死率及低血糖发生率。结果 观察组治疗总有效率为93.50%，与对照组的92.10%比较，差异无统计学意义（P＞0.05）；观察组FBG、HbA1c、BMI、收缩压、舒张压均低于对照组，差异有统计学意义（P＜0.05）；观察组UA、mAlb水平均低于对照组，差异有统计学意义（P＜0.05）；观察组病死率低于对照组，差异有统计学意义（P＜0.05），两组低血糖发生率比较，差异无统计学意义（P＞0.05）。结论 达格列净治疗2型糖尿病效果确切，对肾功能影响较小，病死率低，有助于改善患者预后，安全性较好。
Abstract:
Objective To observe the efficacy and safety of dapagliflozin in the treatment of type 2 diabetes and its impact on body mass index. Methods A total of 153 patients with type 2 diabetes diagnosed and treated in our hospital from April to December 2017 were selected as the research object, and were divided into a control group (n=75) and an observation group (n=78) by random number table. The control group was treated with metformin, and the observation group was treated with dapagliflozin. The therapeutic effect, fasting blood glucose (FBG) level, glycated hemoglobin (HbA1c), body mass index (BMI), blood pressure, and renal function indexes [uric acid (UA), microalbuminuria (mAlb)], mortality and incidence of hypoglycemia.Results The total effective rate of treatment in the observation group was 93.50%, compared with 92.10% in the control group,the difference was not statistically significant (P>0.05); FBG, HbA1c, BMI, systolic blood pressure and diastolic blood pressure in the observation group were lower than the control group, the difference was statistically significant (P<0.05); the UA and mAlb levels of the observation group were lower than the control group, the difference was statistically significant (P<0.05); the mortality rate of the observation group was lower than the control group, the difference was statistically significant (P<0.05), the incidence of hypoglycemia between the two groups was not statistically significant (P>0.05).Conclusion Dapagliflozin has a definite effect on the treatment of type 2 diabetes. It has little effect on renal function and low mortality.

参考文献/References:

[1]中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8):304-305. [2]Alessandro S,Gabriella S,Mattia F,et al．Efficacy and renal safety of dapagliflozin in patients with type 2 diabetes mellitusalso receiving metformin: A real-life experience[J].J Diabetes Res,2018(3):8501418. [3]Sattar N,McLaren J,Kristensen SL,et al.SGLT2 inhibition and ardiovascular events:why did EMPA-REG outcomes surpriseand what were the likely mechanisms[J].Diabetologia,2016,59(7):1333-1339. [4]Hallow KM,Greasley PJ,Helmlinger G,et al.Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data[J].Am J Physiol Renal Physiol,2018,315(5):F1295-F1306. [5]Lin B,Koibuchi N,Hasegawa Y,et al.Glycemic control with empagliflozin,a novel selective SGLT2 inhibitor,ameliorates cardiovaseular injury and cognitive dysfunction in obese and type 2diabetic mice[J].Cardiovasc Diabetol,2014(13):148.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(07):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(07):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(07):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(07):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(07):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(07):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(07):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[8]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(07):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[9]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(07):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[10]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,31(07):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[11]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息,2018,31(19):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
　SUN Shou-guang.Progress in the Study of Dapagliflozin in the Treatment of Type 2 Diabetes[J].Medical Information,2018,31(07):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
[12]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(07):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[13]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2024,37(07):122.[doi:10.3969/j.issn.1006-1959.2024.13.025]
[14]刘 璇,陈珍珍.达格列净联合二甲双胍在2型糖尿病治疗中的临床疗效[J].医学信息,2025,38(02):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]
　LIU Xuan,CHEN Zhenzhen.Clinical Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2025,38(07):116.[doi:10.3969/j.issn.1006-1959.2025.02.021]
[15]黄林娜,闵 松.达格列净对2型糖尿病合并慢性心功能不全患者血糖水平及短期预后的影响[J].医学信息,2025,38(10):138.[doi:10.3969/j.issn.1006-1959.2025.10.027]
　HUANG Linna,MIN Song.Effect of Dapagliflozin on Blood Glucose Level and Short-term Prognosis in Patients with Type 2 Diabetes Mellitus Complicated by Chronic Cardiac Insufficiency[J].Medical Information,2025,38(07):138.[doi:10.3969/j.issn.1006-1959.2025.10.027]
[16]朱 健.卡波糖与达格列净治疗2型糖尿病的临床效果及药物不良反应分析[J].医学信息,2025,38(12):136.[doi:10.3969/j.issn.1006-1959.2025.12.029]
　ZHU Jian.Analysis of Clinical Effect and Adverse Drug Reactions of Acarbose and Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2025,38(07):136.[doi:10.3969/j.issn.1006-1959.2025.12.029]

更新日期/Last Update: 2020-04-01